Acer Therapeutics Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Acer Therapeutics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Acer Therapeutics stock.
View analyst ratings for Acer Therapeutics or view top-rated stocks.

Wall Street analysts have given Acer Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Acer Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Acer Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for Acer Therapeutics.

Acer Therapeutics Inc. (NASDAQ:ACER) announced its quarterly earnings data on Sunday, May, 16th. The biopharmaceutical company reported ($0.11) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.44) by $0.33. The biopharmaceutical company earned $4 million during the quarter, compared to analyst estimates of $2 million.
View Acer Therapeutics' earnings history.

Acer Therapeutics' stock was trading at $3.38 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ACER shares have decreased by 28.7% and is now trading at $2.41.
View which stocks have been most impacted by COVID-19.

64 employees have rated Acer Therapeutics CEO Jason Chen on Glassdoor.com. Jason Chen has an approval rating of 99% among Acer Therapeutics' employees. This puts Jason Chen in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Acer Therapeutics include SELLAS Life Sciences Group (SLS), Orgenesis (ORGS), Odonate Therapeutics (ODT), Neptune Wellness Solutions (NEPT), Purple Biotech (PPBT), Tiziana Life Sciences (TLSA), Aquestive Therapeutics (AQST), Abeona Therapeutics (ABEO), Catalyst Biosciences (CBIO), Anixa Biosciences (ANIX), Enlivex Therapeutics (ENLV), ProMetic Life Sciences (PFSCF), POINT Biopharma Global (PNT), Medicenna Therapeutics (MDNA) and Oncolytics Biotech (ONCY).
View all of ACER's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Acer Therapeutics investors own include Novavax (NVAX), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Sarepta Therapeutics (SRPT), Advanced Micro Devices (AMD), Amarin (AMRN), VBI Vaccines (VBIV), NVIDIA (NVDA), Idera Pharmaceuticals (IDRA) and Inovio Pharmaceuticals (INO).

Acer Therapeutics trades on the NASDAQ under the ticker symbol "ACER."

Shares of ACER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ACER stock can currently be purchased for approximately $2.41.

Acer Therapeutics has a market capitalization of $34.49 million. The biopharmaceutical company earns $-22,890,000.00 in net income (profit) each year or ($2.06) on an earnings per share basis.

Acer Therapeutics employs 21 workers across the globe.

The official website for Acer Therapeutics is www.acertx.com.

Acer Therapeutics is headquartered at 300 WASHINGTON STREET SUITE 351, NEWTON MA, 02458.

Acer Therapeutics' mailing address is 300 WASHINGTON STREET SUITE 351, NEWTON MA, 02458. The biopharmaceutical company can be reached via phone at (844) 902-6100 or via email at [email protected]